Plaque Psoriasis – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032
Plaque
psoriasis (PS), also known as psoriasis vulgaris, is the most common form of
psoriasis, accounting for 80–90% of cases. The lesions are characteristically
well-defined, erythematous, scaly plaques and often have the distribution
detailed above (elbows, knees, scalp, inter-gluteal cleft). The plaques vary in
size, and patients may present with only a few lesions or with a widely
generalized disease. Lesions are often symmetrically distributed. Mild to
moderate disease, classified as involving less than 10% of the BSA, represents
approximately 80% of cases of plaque psoriasis.
- The prevalence of
psoriasis in the USA ranges from 2.1% to 2.73%, which is slightly higher
from a global perspective.
Thelansis’s “Plaque Psoriasis (PS)
Market Outlook, Epidemiology, Competitive
Landscape, and Market Forecast Report – 2021 To 2032" covers disease
overview, epidemiology, drug utilization, prescription share analysis,
competitive landscape, clinical practice, regulatory landscape, patient share,
market uptake, market forecast, and key market insights under the potential Plaque
Psoriasis (PS) treatment modalities options for eight major markets (USA,
Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights
of Plaque Psoriasis across 8 MM market from the centre of Excellence/ Public/
Private hospitals participated in the study. Insights around current treatment
landscape, epidemiology, clinical characteristics, future treatment paradigm,
and Unmet needs.
Plaque Psoriasis Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment